Future Retirement Success
  • Politics
  • Business
  • Investing
  • Stocks
  • Politics
  • Business
  • Investing
  • Stocks

Future Retirement Success

Investing

The White House Addresses Tranq While Lawmakers Fight The Last Battle Against Fentanyl Analogs

by July 11, 2023
July 11, 2023

Jeffrey A. Singer

Last May, the U.S. House of Representatives passed the HALT Fentanyl Act, a futile attempt to address the overdose crisis by classifying as Schedule 1 drugs any new analogs of fentanyl (called “fentanyl‐​related substances” or “FRSs”) that the drug cartels synthesize in clandestine labs, and increasing mandatory minimum sentences for people found to possess them. As I told the House Judiciary Subcommittee on Crime and Government Surveillance when I testified in March,

Fentanyl is just the latest manifestation of what drug policy analysts call “the iron law of prohibition.”A variant of what economists call the Alchian‐​Allen Effect, the shorthand version of the iron law states, “the harder the law enforcement, the harder the drug.” Enforcing prohibition incentivizes those who market prohibited substances to develop more potent forms that are easier to smuggle in smaller sizes and can be subdivided into more units to sell… The iron law of prohibition cannot be repealed. Already we have been getting troubling reports of the veterinary tranquilizer xylazine—drug users call it “tranq”—becoming an additive to fentanyl and other illicit narcotics. This tranquilizer greatly potentiates opioids’ effects, producing more powerful “highs.” Adding this potentiator again enables illicit opioids to be smuggled in smaller sizes and subdivided into more units to sell. (Emphasis added)

Today the White House Office of National Drug Control Policy released a “response plan to address the emerging threat of fentanyl combined with xylazine.” The White House press release revealed that deaths from fentanyl mixed with xylazine—what users call tranq—increased 276 percent between January 2019 and June 2022. By then, roughly 11 percent of all fentanyl‐​related overdoses contained xylazine.

The ONDCP plan includes worthy harm reduction recommendations, such as making it easier for users to test their drugs for xylazine. The makers of fentanyl test strips have already developed xylazine test strips, but, unfortunately, many states still outlaw drug testing equipment or devices as drug paraphernalia. While many states have recently removed fentanyl test strips from their list of illegal paraphernalia, their lawmakers would need next to remove xylazine test strips from that list. It would be wiser for states to remove all testing equipment and devices from their lists of banned paraphernalia. Even better, as Minnesota recently did, they should repeal their paraphernalia laws altogether.

The ONDCP plan, however, makes the same mistake that the members of the House of Representatives made when they passed the HALT Fentanyl Act. Their plan proposes to “explore scheduling and other regulatory actions.” From page 9 of the plan:

Progress toward decisions on possible regulatory actions under the Controlled Substances Act, including scheduling of xylazine while simultaneously maintaining the legitimate supply of xylazine in veterinary medicine, and prioritizing facilitation of access to xylazine for research purposes. The government will also consider other potential avenues for prosecuting those who manufacture, import, export, sell, or distribute xylazine in order to support fentanyl trafficking.

Discuss whether any potential regulatory actions should be xylazine‐​specific or for a broader class of drugs or pharmacologically similar substances that could replace xylazine as a fentanyl adulterant.

Placing xylazine on the Drug Enforcement Administration’s controlled substances schedule will do nothing to deter its use in the drug trade—any more than designating marijuana, heroin, psychedelics, or FRSs as Schedule 1 has deterred buyers and sellers.

The ONDCP plan also calls for greater efforts to “support interdiction.” The U.S. has been waging war on drugs with greater interdiction efforts for over half a century, and drugs are cheaper, more potent, and more available than ever before. Doing the same thing repeatedly and expecting a different result is incompatible with reality.

Drug prohibition and the dangerous and lucrative black market it creates cause the overdose crisis.

Today’s report on the worsening xylazine crisis validates my admonition to lawmakers last March. The House’s passing of the HALT Fentanyl Act was another example of fighting the last battle. The lawmakers hoped to reduce overdose deaths by designating analogs of fentanyl as Schedule 1 when the drug cartels had already moved on to xylazine. As long as policymakers continue enforcing prohibition, another drug crisis from another drug will be in the queue.

0
FacebookTwitterGoogle +Pinterest
previous post
The Halftime Show: Screening for the Strongest Oversold Bullish Stocks
next post
Milwaukee clears 2-cent sales tax hike in bid to avoid bankruptcy

You may also like

St. Louis’ Little Trolley That Couldn’t

November 29, 2023

Three Takeaways from Tech Policy in 2023 and...

January 3, 2024

Higher Education in Libertarian Land

January 16, 2024

The Crypto Tax Rules Proposed by Senators Lummis...

July 28, 2023

Argentina’s Paradigm Shift

November 21, 2023

Content Creators, Entrepreneurship, and Tech Policy

May 1, 2025

American Compass Dystopia: Finance’s “Disproportionate Share” Of Profits

July 18, 2023

Congress Has Questions about California High-Speed Rail

June 3, 2024

The Case Against Raiding Private Savings To Prop...

February 1, 2024

Biden Didn’t Cause the Border Crisis, Part 2:...

January 16, 2025

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Good Riddance to the Penny

      June 5, 2025
    • Oracle Fusion Testing: The UK Leader’s Playbook for Automation

      June 5, 2025
    • Blue state Republicans threaten rebellion if Senate changes key provision in Trump’s ‘big, beautiful bill’

      June 5, 2025
    • Ricketts, Fetterman team up for crackdown on China’s attempts to purchase US farmland

      June 5, 2025
    • Hamas working to ‘sabotage’ Trump-backed aid group with ‘fake news’: Israeli official

      June 5, 2025
    • Longtime Trump loyalist flips on GOP’s ‘big, beautiful bill’

      June 5, 2025

    Categories

    • Business (8,148)
    • Investing (2,009)
    • Politics (15,529)
    • Stocks (3,128)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: futureretirementsuccess.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 futureretirementsuccess.com | All Rights Reserved